Phio Pharmaceuticals
King Of Prussia
About Phio Pharmaceuticals
Phio Pharmaceuticals is a biotechnology company specializing in the application of RNAi therapies in immuno-oncology. Its proprietary INTASYL technology is a platform for self-delivering RNAi immuno-oncology therapies. It is a patented platform from which unique patented compounds are created to silence genes that tumors use to evade the immune system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $138.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:PHIO
- Website: phiopharma.com
- Phone: 610-947-0251
Industries & Categories
Biotechnology, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/phio-pharmaceuticals-60285 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.